28 November 2012
Vol 4, Issue 162

About The Cover

Cover image expansion

ONLINE COVER Boosting Metabolism. Fibroblast growth factor 21 (FGF21) is known to induce weight loss and to regulate blood glucose and insulin levels. However, the native protein is not suitable as a therapeutic. In this issue, Foltz et al. engineered a monoclonal antibody (in pink) that mimics the activity of FGF21 by binding the FGF receptor, thus reducing body weight, plasma lipids, and stabilizing glucose and insulin levels in monkeys. With well-characterized binding and pharmacokinetic profiles, this FGF21-mimetic antibody is a potential therapeutic for treating human diabetes and obesity. [CREDIT: D. EVANS AND J. KEYSOR/SURFMEDIA ENTERPRISES, LLC]